|
|||||||||||||||||||||||||||||||||||||
 |
|
|
Areas of Expertise Scientists and physicians of the Parker Hughes Institute and Parker Hughes Cancer Center have significant expertise in the development of new agents and new treatment strategies for the treatment of cancer. The Institute is most noted for its development of several new agents for the treatment of leukemias. These agents have shown effectiveness in the treatment of childhood and adult leukemias and lymphomas. New agents are currently in clinical trials for the following: Acute Lymphocytic Leukemia Acute Myelogenous Leukemia Chronic Myelogenous Leukemia Chronic Lymphocytic Leukemia Plasma Cell Leukemia Hairy Cell Leukemia Childhood Cancer In addition to the state-of-the-art treatment strategies currently offered, new agents are under development for the following: Bladder Cancer Breast Cancer Childhood Leukemia Colon Cancer Leukemia Lung Cancer Lymphoma Melanoma Ovarian Cancer Prostate Cancer Rectal Cancer Sarcomas Thyroid Cancer |
|
|
|
 |
||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||
